Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In additi...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-07-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/full |
id |
doaj-7e8e43bdcb734477aeaad284246cb0b8 |
---|---|
record_format |
Article |
spelling |
doaj-7e8e43bdcb734477aeaad284246cb0b82021-07-01T15:02:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.620187620187Tocilizumab in COVID-19: Factors Associated With Mortality Before and After TreatmentLuis Sarabia De Ardanaz0Jose M. Andreu-Ubero1Miriam Navidad-Fuentes2Miguel Ángel Ferrer-González3Victor Ruíz del Valle4Inmaculada Salcedo-Bellido5Inmaculada Salcedo-Bellido6Inmaculada Salcedo-Bellido7Rocío Barrios-Rodríguez8Rocío Barrios-Rodríguez9Rocío Barrios-Rodríguez10Rafael Cáliz-Cáliz11Pilar Requena12Departamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, EspañaInstituto de Investigación Biosanitaria (ibs.Granada), Granada, SpainConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SpainDepartamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, EspañaInstituto de Investigación Biosanitaria (ibs.Granada), Granada, SpainConsortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainDepartamento de Reumatología, Hospital Universitario Virgen de las Nieves, Granada, SpainTocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23–5.64), age (HR 1.05; 95% CI 1.02–1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00–1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p = 0.013), troponin I (p = 0.013), C-reactive protein (p = 0.013), neutrophils (p = 0.024), and fewer platelets (p = 0.013) and lymphocytes (p = 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters.https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/fullCOVID-19immunosupressiontocilizumabmortalityrisk factorplatelet |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Luis Sarabia De Ardanaz Jose M. Andreu-Ubero Miriam Navidad-Fuentes Miguel Ángel Ferrer-González Victor Ruíz del Valle Inmaculada Salcedo-Bellido Inmaculada Salcedo-Bellido Inmaculada Salcedo-Bellido Rocío Barrios-Rodríguez Rocío Barrios-Rodríguez Rocío Barrios-Rodríguez Rafael Cáliz-Cáliz Pilar Requena |
spellingShingle |
Luis Sarabia De Ardanaz Jose M. Andreu-Ubero Miriam Navidad-Fuentes Miguel Ángel Ferrer-González Victor Ruíz del Valle Inmaculada Salcedo-Bellido Inmaculada Salcedo-Bellido Inmaculada Salcedo-Bellido Rocío Barrios-Rodríguez Rocío Barrios-Rodríguez Rocío Barrios-Rodríguez Rafael Cáliz-Cáliz Pilar Requena Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment Frontiers in Pharmacology COVID-19 immunosupression tocilizumab mortality risk factor platelet |
author_facet |
Luis Sarabia De Ardanaz Jose M. Andreu-Ubero Miriam Navidad-Fuentes Miguel Ángel Ferrer-González Victor Ruíz del Valle Inmaculada Salcedo-Bellido Inmaculada Salcedo-Bellido Inmaculada Salcedo-Bellido Rocío Barrios-Rodríguez Rocío Barrios-Rodríguez Rocío Barrios-Rodríguez Rafael Cáliz-Cáliz Pilar Requena |
author_sort |
Luis Sarabia De Ardanaz |
title |
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment |
title_short |
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment |
title_full |
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment |
title_fullStr |
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment |
title_full_unstemmed |
Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment |
title_sort |
tocilizumab in covid-19: factors associated with mortality before and after treatment |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2021-07-01 |
description |
Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23–5.64), age (HR 1.05; 95% CI 1.02–1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00–1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p = 0.013), troponin I (p = 0.013), C-reactive protein (p = 0.013), neutrophils (p = 0.024), and fewer platelets (p = 0.013) and lymphocytes (p = 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters. |
topic |
COVID-19 immunosupression tocilizumab mortality risk factor platelet |
url |
https://www.frontiersin.org/articles/10.3389/fphar.2021.620187/full |
work_keys_str_mv |
AT luissarabiadeardanaz tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT josemandreuubero tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT miriamnavidadfuentes tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT miguelangelferrergonzalez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT victorruizdelvalle tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT inmaculadasalcedobellido tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT inmaculadasalcedobellido tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT inmaculadasalcedobellido tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT rociobarriosrodriguez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT rociobarriosrodriguez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT rociobarriosrodriguez tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT rafaelcalizcaliz tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment AT pilarrequena tocilizumabincovid19factorsassociatedwithmortalitybeforeandaftertreatment |
_version_ |
1721346944333250560 |